Monkeypox - 9 Studies Found
| Completed |
: IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo : Monkeypox Virus Infection : 2016-09-07 : Biological: IMVAMUNE® Two doses of attenuated live virus smallpox vaccine (IMVAMUNE®) administ |
| Available |
: Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure :
: 2014-03-04 : Drug: Tecovirimat Oral tablet 600mg daily dose(three capsules, 200 mg/capsule) |
| Completed |
: Phase I Trial of an Investigational Small Pox Medication :
|
| Completed |
: A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses :
|
| Withdrawn |
: SIGA-246 to Treat Smallpox : Vaccinia : 2006-03-14 : Drug: Vaccine: SIGA-246 |
| Completed |
: A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines : Monkeypox : 2025-11-04 : Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection |
| ACTIVE_NOT_RECRUITING |
: A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox : Monkeypox : 2025-11-04 : JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States.JYNNEOS is a live vaccine produced from the strain |
| Completed |
: Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV : Monkeypox : 2025-11-04 |
| COMPLETED |
: Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only : Mpox (Monkeypox) : 2025-11-04 : Tecovirimat Oral Capsule 200 mg capsulesNumber of capsules and frequency of dosage will be based on participant weight:
|